The Latest Breaking News on Pharma

Federal judge in Texas ruled in early April to suspend FDA-approved mifepristone used in more than half of abortions in US

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

WASHINGTON — The Supreme Court gave itself more time on a decision expected Wednesday about a commonly used abortion drug, extending until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

A generic-mifepristone maker sued the U.S. Food and Drug Administration to protect access to the medical abortion pill amid a welter of litigation stretching from Texas to Washington.

The court has given itself until Friday to rule on whether to allow restrictions to take effect on mifepristone as legal challenges to its FDA approval continue.

GenBioPro, which makes a generic form of mifepristone, is suing the FDA seeking to preserve access to the drug amidst ongoing federal litigation.

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

TRADE Unions have agreed to urge Labour to include a commitment to devolve drug powers to Scotland in their next General Election manifesto.

After Insulet jumped on news it was joining the S&P 500, PODD stock is wound up for a breakout with earnings due.